The conundrum of anti-angiogenesis in cancer
“Anti-angiogenesis in cancer is something of a conundrum where the unexpected is to be expected.”...
Thrombosis and cancer
Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer
The authors of a recent study1 have taken a novel look at the impact of venous thromboembolism (VTE) among...
CAT Studies
The following list contains a selection of the most recent clinical trials about cancer-associated thrombosis....
Cancer’s Achilles heel exposed
Centriole amplification and centriole size deregulation are a recurrent feature of cancer cells, a screening of the...
The quest for personalized management of thrombosis in cancer – do cancer genes hold the clue?
Cancer associated thrombosis (CAT) is perplexing. Spite of over 150 years of recorded history, considerable prevalence...
Bleeding complications and platelet dysfunction in patients with lymphoproliferative disease receiving Bruton tyrosine kinase inhibitors
Ibrutinib (IBR) is an irreversible inhibitor of Bruton tyrosine kinase (Btk) that is approved for the treatment of...
Managing antithrombotic medication in thrombocytopenia
Cancer is associated with an increased risk of venous but also arterial thrombosis1. Moreover, contemporary anticancer...
Anticoagulants for cancer survival
Max is a 61-year-old male who works as a consultant cardiologist at your same institution and who has recently been...
New perspectives for the treatment of cancer-associated thrombosis
New perspectives for the treatment of cancer-associated thrombosis Patients with cancer-associated thrombosis (CAT)...
Trial updates In thromboprophylaxis of cancer-related venous thromboembolism
The past decade has seen a large number of studies focusing on identifying cancer patients at high risk for venous...